CNSP (CNS Pharmaceuticals) Cash per Share : $10.42 (As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is CNS Pharmaceuticals Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). CNS Pharmaceuticals's Cash per Share for the quarter that ended in Sep. 2024 was $10.42.

CNS Pharmaceuticals Cash per Share Historical Data

The historical data trend for CNS Pharmaceuticals's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CNS Pharmaceuticals Cash per Share Chart

CNS Pharmaceuticals Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash per Share

Get a 7-Day Free Trial

10,055.00

274.50

CNS Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash per Share	Get a 7-Day Free Trial															455.00	274.50	203.75	51.45	10.42

CNS Pharmaceuticals Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

CNS Pharmaceuticals's Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	0.549	/	0.00
	=	274.50

CNS Pharmaceuticals's Cash per Share for the quarter that ended in Sep. 2024 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	6.973	/	0.67
	=	10.42

CNS Pharmaceuticals (NAS:CNSP) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

CNS Pharmaceuticals Cash per Share Related Terms

Thank you for viewing the detailed overview of CNS Pharmaceuticals's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

CNS Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CNS Pharmaceuticals Inc (NAS:CNSP) » Definitions » Cash per Share

Comparable Companies

Traded in Other Exchanges

BE5:Germany

Address

2100 West Loop South, Suite 900, Houston, TX, USA, 77027

Website

https://www.cnspharma.com

CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.

Executives

Christopher Downs	officer: Chief Financial Officer	31700 RESEARCH PARK DRIVE, MADISON HEIGHTS MI 48071
John M Climaco	director, officer: Chief Executive Officer	PO BOX 326, PARK CITY UT 84060
Carl Anthony Evans	director	C/O CNS PHARMACEUTICALS, INC., 2100 WEST LOOP SOUTH STE 900, HOUSTON TX 77027
Jerzy Gumulka	director	C/O CNS PHARMACEUTICALS, INC., 2100 WEST LOOP SOUTH STE 900, HOUSTON TX 77027
Bettina M. Cockroft	director	C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Waldemar Priebe	10 percent owner	2575 W. BELLFORT, SUITE 333, HOUSTON TX 77054
Faith L. Charles	director	ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019
Jeffry R. Keyes	director	13950 STOWE DRIVE, POWAY CA 92064-8803
Andrzej Andraczke	director	C/O CNS PHARMACEUTICALS, INC., 2100 WEST LOOP SOUTH STE 900, HOUSTON TX 77027